View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
May 27, 2021updated 12 Jul 2022 11:13am

Janssen’s Darzalex Faspro yields positive data in AL amyloidosis trial

Janssen’s Darzalex Faspro offers improved haematologic complete response in Phase III AL amyloidosis trial.

Janssen Pharmaceutical has reported follow-up results from Phase III ANDROMEDA study where its Darzalex Faspro (daratumumab and hyaluronidase-fihj) offered improved haematologic complete response (hemCR) in newly diagnosed light chain (AL) amyloidosis patients.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Darzalex Faspro is a CD38-directed antibody that received accelerated approval from the US Food and Drug Administration in combination with bortezomib (Velcade), cyclophosphamide and dexamethasone (VCd) for treating AL amyloidosis patients.

This FDA approval is based on initial data, including response rate findings, from the Phase III study.

AL amyloidosis is a rare blood cell disease that affects the function and causes deterioration of vital organs, mainly the heart, kidneys and liver.

The ongoing, randomised, open-label Phase III ANDROMEDA trial is assessing the safety and efficacy of Darzalex Faspro plus VCd (D-VCd), versus VCd alone, in 388 adult patients with AL amyloidosis.

With a median follow up of 20.3 months, longer-term data demonstrated rates of hemCR were increased in subjects receiving D-VCd versus VCd alone.

At a median follow-up of 11.4 months, hemCR was observed to be 53% and 18% in D-VCd arm and VCd arm, respectively, while at 20.3 months, the rates rose to 59% and 19%, respectively.

Furthermore, 79% of subjects in the D-VCd arm showed a very good partial response or better compared to 50% in the VCd arm after 20.3 months of median follow-up.

No new safety signals of Darzalex Faspro were noted in the trial while the most common adverse reactions were found to be diarrhoea, peripheral oedema, constipation and peripheral sensory neuropathy, among others.

Janssen Research & Development Clinical Development vice-president Jessica Vermeulen said: “These updated efficacy and safety results show the potential impact Darzalex Faspro can have in treating AL amyloidosis.

“Following the FDA approval earlier this year, these latest data are a result of our commitment to further exploring the potential of Darzalex in haematologic and rare diseases for patients in need of new options.”

This development comes after Janssen reported follow-up results from the Phase I MajesTEC-1 dose-escalation study, where its investigational antibody, teclistamab, provided durable responses in relapsed or refractory multiple myeloma patients.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena